Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD
Status:
Completed
Trial end date:
2018-03-08
Target enrollment:
Participant gender:
Summary
Despite the availability of a wide range of antidepressant drugs, clinical trials indicate
that 30% to 40% of patients with major depression fail to respond to first-line
antidepressant treatment, despite adequate dosage, duration, and compliance. Moreover, in
those patients who do experience symptomatic relief following conventional anti-depressant
treatment, clinical improvement is not evident for 3-4 weeks. Thus, there is a clear need to
develop novel and improved therapeutics for unipolar depression.
A previous study showed that the intravenous administration of scopolamine produces
antidepressant effects. This study is designed to determine if scopolamine combine with
Escitalopram produce antidepressant effects at an early stage.